Indication:
Tresiba® is indicated for once-daily treatment of adults with diabetes mellitus to improve glycemic control.
Tresiba® is also indicated for the treatment of pediatric patients (>2 years old) with type 1 diabetes mellitus.
Clinical use:
Not recommended for treatment of diabetic ketoacidosis.
Contraindication:
- During episodes of hypoglycemia
Most serious warnings and precautions:
Hypoglycemia is the most common adverse effect of insulin
- Glucose monitoring is required
- Uncorrected hypo- or hyperglycemic reactions can cause loss of consciousness, coma and even death
- Use caution and medical supervision when converting insulin products
Administration
- Inspect visually prior to administration and only use if solution appears clear and colourless
- Do not mix with any other insulin, administer intravenously or use in insulin infusion pumps
Other relevant warnings and precautions:
- Refer to respective product monographs for concomitant oral antidiabetic agents for their warnings and precautions
- Stress or concomitant illness, especially infections and febrile conditions, may change insulin requirements
- Tresiba® should not be diluted
- Combination with thiazolidinediones (TZD) not indicated in type 2 diabetes; can cause heart failure and edema
- Risks associated with sharing insulin delivery devices
- Hyperglycemia
- Risk of hypokalemia
- Dosing may need to be adjusted in patients with renal and/or hepatic impairment
- Risk of immune responses (e.g., systemic allergic reactions or antibody production)
- Pregnant and nursing women
- Pediatrics
- Geriatrics
For more information:
Please consult the Product Monograph at www.Tresibapm-e.ca for more information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.
The Product Monograph is also available by calling us at 1-800-465-4334.
